Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Denali Therapeutics Q3 2026 Results: Turns Profitable, Net Income $70.1M

Denali Therapeutics reported a net income of $70.1 million for the third quarter of 2026, driven by a $194.0 million gain from the sale of a priority review voucher. However, the company recorded a net loss of $185.9 million for the first nine months of 2026, reflecting ongoing heavy investment in research and development and the initial recognition of product revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue17.80.0
Net income70.1-126.9
EPS (diluted, $ a share)$0.37$-0.74

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DNLI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Denali Therapeutics Inc.: key numbers

Share price
$18.08Close, Nov 16
Market cap
$2.9B
Shares outstanding
160.29MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Denali Therapeutics Inc.

All →
4:04 PM ET 8-K
Financial Results

Denali Therapeutics Financial Results

Denali Therapeutics reported Q3 2026 financial results, highlighted by $17.8 million in net product revenue for AVLAYAH and a net income of $70.1 million. The company's cash position reached $1.0 billion, bolstered by a $194.0 million net gain from the sale of a Priority Review Voucher.

Term
Q3 2026

“Families and physicians are telling us that AVLAYAH is making a difference for children with Hunter syndrome, and the results this quarter reflect that. The positive responses to AVLAYAH across patients, physicians and payers, and our team’s strong commercial execution, show what is possible for our TransportVehicle portfolio.”

Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.